434 related articles for article (PubMed ID: 31799875)
1. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
[No Abstract] [Full Text] [Related]
2. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
3. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy.
Ciaravino V; Cardobi N; DE Robertis R; Capelli P; Melisi D; Simionato F; Marchegiani G; Salvia R; D'Onofrio M
Anticancer Res; 2018 Aug; 38(8):4889-4895. PubMed ID: 30061265
[TBL] [Abstract][Full Text] [Related]
4. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
5. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
6. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
7. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H
Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151
[TBL] [Abstract][Full Text] [Related]
9. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
[TBL] [Abstract][Full Text] [Related]
10. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma - a quantitative analysis.
Eilaghi A; Baig S; Zhang Y; Zhang J; Karanicolas P; Gallinger S; Khalvati F; Haider MA
BMC Med Imaging; 2017 Jun; 17(1):38. PubMed ID: 28629416
[TBL] [Abstract][Full Text] [Related]
11. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience.
Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H
Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389
[TBL] [Abstract][Full Text] [Related]
12. Resectable pancreatic adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes.
Cassinotto C; Chong J; Zogopoulos G; Reinhold C; Chiche L; Lafourcade JP; Cuggia A; Terrebonne E; Dohan A; Gallix B
Eur J Radiol; 2017 May; 90():152-158. PubMed ID: 28583627
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer.
Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J
Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297
[TBL] [Abstract][Full Text] [Related]
15. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
16. CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes.
Lubner MG; Stabo N; Abel EJ; Del Rio AM; Pickhardt PJ
AJR Am J Roentgenol; 2016 Jul; 207(1):96-105. PubMed ID: 27145377
[TBL] [Abstract][Full Text] [Related]
17. Prediction of overall survival in patients with pancreatic ductal adenocarcinoma: histogram analysis of ADC value and correlation with pathological intratumoral necrosis.
Noda Y; Tomita H; Ishihara T; Tsuboi Y; Kawai N; Kawaguchi M; Kaga T; Hyodo F; Hara A; Kambadakone AR; Matsuo M
BMC Med Imaging; 2022 Feb; 22(1):23. PubMed ID: 35135492
[TBL] [Abstract][Full Text] [Related]
18. Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase.
Reinert CP; Baumgartner K; Hepp T; Bitzer M; Horger M
Abdom Radiol (NY); 2020 Mar; 45(3):750-758. PubMed ID: 31953587
[TBL] [Abstract][Full Text] [Related]
19. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis.
Kim BR; Kim JH; Ahn SJ; Joo I; Choi SY; Park SJ; Han JK
Eur Radiol; 2019 Jan; 29(1):362-372. PubMed ID: 29931561
[TBL] [Abstract][Full Text] [Related]
20. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
